These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

77 related items for PubMed ID: 8104437

  • 1. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.
    Kern JA, Torney L, Weiner D, Gazdar A, Shepard HM, Fendly B.
    Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437
    [Abstract] [Full Text] [Related]

  • 2. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
    Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM.
    Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
    [Abstract] [Full Text] [Related]

  • 3. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D, Mendelsohn J, Fan Z.
    Oncogene; 1999 Jan 21; 18(3):731-8. PubMed ID: 9989823
    [Abstract] [Full Text] [Related]

  • 4. Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines.
    Kopreski MS, Lipton A, Harvey HA, Kumar R.
    Anticancer Res; 1996 Jan 21; 16(1):433-6. PubMed ID: 8615649
    [Abstract] [Full Text] [Related]

  • 5. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
    Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM.
    Cancer Immunol Immunother; 1993 Sep 21; 37(4):255-63. PubMed ID: 8102322
    [Abstract] [Full Text] [Related]

  • 6. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
    Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A.
    Cancer Res; 1990 Mar 01; 50(5):1550-8. PubMed ID: 1689212
    [Abstract] [Full Text] [Related]

  • 7. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
    Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA.
    Oncogene; 2000 Jul 20; 19(31):3460-9. PubMed ID: 10918604
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of p185HER2 expression in human non-small cell lung cancer cell lines.
    Kern JA, Robinson RA, Gazdar A, Torney L, Weiner DB.
    Am J Respir Cell Mol Biol; 1992 Apr 20; 6(4):359-63. PubMed ID: 1312850
    [Abstract] [Full Text] [Related]

  • 9. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells.
    Kumar R, Shepard HM, Mendelsohn J.
    Mol Cell Biol; 1991 Feb 20; 11(2):979-86. PubMed ID: 1671297
    [Abstract] [Full Text] [Related]

  • 10. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
    Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA, Ullrich A.
    J Clin Immunol; 1991 May 20; 11(3):117-27. PubMed ID: 1679763
    [Abstract] [Full Text] [Related]

  • 11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 12. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling.
    Oelmann E, Sreter L, Schuller I, Serve H, Koenigsmann M, Wiedenmann B, Oberberg D, Reufi B, Thiel E, Berdel WE.
    Cancer Res; 1995 May 15; 55(10):2212-9. PubMed ID: 7538048
    [Abstract] [Full Text] [Related]

  • 13. Ligand-like effects induced by anti-c-erbB-2 antibodies do not correlate with and are not required for growth inhibition of human carcinoma cells.
    Shawver LK, Mann E, Elliger SS, Dugger TC, Arteaga CL.
    Cancer Res; 1994 Mar 01; 54(5):1367-73. PubMed ID: 7907001
    [Abstract] [Full Text] [Related]

  • 14. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 01; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 15. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.
    Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, Wang Q, Kao G, O'Rourke DM, Greene MI, Murali R.
    Nat Biotechnol; 2000 Feb 01; 18(2):194-8. PubMed ID: 10657127
    [Abstract] [Full Text] [Related]

  • 16. Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells.
    Campiglio M, Tagliabue E, Srinivas U, Pellegrini R, Martignone S, Ménard S, Colnaghi MI, Lombardi L, Marchisio PC.
    J Cell Biochem; 1994 Aug 01; 55(4):409-18. PubMed ID: 7962174
    [Abstract] [Full Text] [Related]

  • 17. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J.
    Clin Cancer Res; 1997 Nov 01; 3(11):2099-106. PubMed ID: 9815602
    [Abstract] [Full Text] [Related]

  • 18. Binding-induced activation of overexpressed p185HER2 is essential in triggering neuronal differentiation of PC12 cells.
    Orlandi R, Formantici C, Colnaghi MI, Ménard S.
    J Cell Biochem; 1997 Dec 01; 67(3):316-26. PubMed ID: 9361187
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.